Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849910 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
A Phase 1 study, sponsored by Vor Biopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT04849910 is a Phase 1 study that was terminated before completion, run by Vor Biopharma. The registered enrollment target is 67 participants.
The verdict
NCT04849910, a Phase 1 study, was terminated before completion, sponsored by Vor Biopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Interventions
- DRUG Mylotarg
- BIOLOGICAL VOR33
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04849910
The ClinicalTrials.gov registry entry for NCT04849910 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vor Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mylotarg is the first listed.
NCT04849910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04849910 about?
NCT04849910 is a clinical study titled "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS". This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
What is the current status of trial NCT04849910?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2021-12-16. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT04849910?
The interventions under investigation include: Mylotarg (DRUG), VOR33 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04849910?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.